BN Business News
Add your company to Business Communicator →

Business · 15/10/2012

National Institutes of Health to Grant Exclusive License for Anti-CD22 CARs for B Cell Malignancies Treatment

The National Institutes of Health is considering granting an exclusive license to practice inventions related to anti-CD22 chimeric antigen receptors (CARs) for the treatment of B cell malignancies, as outlined in U.S. Patent Applications and patents.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Explore insights